Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Prospective Multicenter, Double Blind, Parallel Assignment Placebo Controlled BE Study Of Naftifine Hydrochloride 2% Topical Cream With Naftin® In Patients With Tinea Pedis Using Clinical Endpoints

NCT02633813 is registered in ClinicalTrials.gov with Genzum Life Sciences as lead sponsor.

NCT NCT02633813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02633813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Prospective Multicenter, Double Blind, Parallel Assignment Placebo Controlled BE Study Of Naftifine Hydrochloride 2% Topical Cream With Naftin® In Patients With Tinea Pedis Using Clinical Endpoints
Lead sponsor
Genzum Life Sciences
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2015
Completion date
December 31, 2015
Enrollment
693 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

tinea pedis